March 11, 2009
Biotech, cancer, Inflammation Luke Timmerman wrote: Some members of the band that pumped out a one-hit wonder at Icos are getting back together to see if they can produce at least one more hit at Seattle-based Calistoga Pharmaceuticals. Calistoga has been building up its management team over the pas...
Xconomy
[ Feed -
Focus -
Exclude ]
by
Luke Timmerman
at 10:00 AM
| 2 Citations
March 06, 2009
Biotech, cancer, Drugs Luke Timmerman wrote: Nowhere but America makes it possible for a company to pursue its dreams for 28 years without making a profit. Even in the most optimistic times, it’s hard to explain. So how can it possibly be, in the depths of recession, that things are looking up...
Xconomy
[ Feed -
Focus -
Exclude ]
by
Luke Timmerman
at 6:00 AM
| 2 Citations
March 05, 2009
cleantech, energy, wind Luke Timmerman wrote: British Columbia is bigger in land area than Washington, Oregon, and California combined, but has about one-tenth the total population. Yet pound-for-pound, our neighbor to the north appears to have its share of entrepreneurs thinking hard about energy a...
Xconomy
[ Feed -
Focus -
Exclude ]
by
Luke Timmerman
at 5:00 AM
| 5 Citations
March 03, 2009
cleantech, energy, environment Luke Timmerman wrote: The venture capitalist John Doerr of Kleiner Perkins Caufield & Byers said three years ago that “greentech could be the largest economic opportunity of the 21st century.” Since then, voters in the U.S. have elected a President and ...
Xconomy
[ Feed -
Focus -
Exclude ]
by
Luke Timmerman
at 9:13 AM
| 6 Citations
March 02, 2009
Biotech, FDA, Life Sciences Luke Timmerman wrote: Genzyme got some bad news today from the FDA. The Cambridge, MA-based biotech company said that U.S. regulators determined its drug for Pompe disease made in large-scale vats isn’t ready to be approved for the market. Plus, the FDA sent the com...
Xconomy
[ Feed -
Focus -
Exclude ]
by
Luke Timmerman
at 6:25 PM
| 2 Citations
February 26, 2009
Biotech, cancer, Melanoma Luke Timmerman wrote: Synta Pharmaceuticals reported some disastrous news this afternoon. The Lexington, MA-based biotech company (NASDAQ: SNTA) said it has halted a clinical trial involving more than 630 cancer patients because a greater number of people died after taking ...
Xconomy
[ Feed -
Focus -
Exclude ]
by
Luke Timmerman
at 5:22 PM
| 3 Citations
Biotech, cancer, Drugs Luke Timmerman wrote: Off the coast of the Bahamas, in sea grass more than a half-mile deep, San Diego-based Nereus Pharmaceuticals found a fungus that may be the key ingredient for an innovative new cancer drug. This will be a key year for gathering evidence that will either ...
Xconomy
[ Feed -
Focus -
Exclude ]
by
Luke Timmerman
at 5:00 AM
| 1 Citations
February 24, 2009
Biotech, Lupus, Diagnostics Luke Timmerman wrote: Cypress Bioscience (NASDAQ: CYPB), the San Diego-based developer of a drug for fibromyalgia, said today it has acquired technology from Cellatope to diagnose and monitor hard-to-detect autoimmune diseases like lupus. Cypress and its partner, New York...
Xconomy
[ Feed -
Focus -
Exclude ]
by
Luke Timmerman
at 10:07 AM
| 1 Citations
February 23, 2009
Biotech, Patents, vaccines Luke Timmerman wrote: One of the world’s best-selling vaccines, Merck’s Gardasil, is quietly producing some serious money for an unexpected benefactor—the University of Washington. Thanks to some hard-fought patent litigation from the 1990s that ended up ...
Xconomy
[ Feed -
Focus -
Exclude ]
by
Luke Timmerman
at 3:00 AM
| 3 Citations
February 17, 2009
Biotech, VC, Life Sciences Luke Timmerman wrote: There are easier things to do these days than trying to organize a biotech investing conference in Seattle. The local cluster has taken its share of body blows, the weather is usually pretty gray in late winter, and investors aren’t in the mood ...
Xconomy
[ Feed -
Focus -
Exclude ]
by
Luke Timmerman
at 2:05 AM
| 4 Citations
